SANGUINATE

DRUG5 trials

Sponsors

Prolong Pharmaceuticals

Conditions

Anemia, Sickle CellDelayed Function of Renal TransplantLeg UlcerRenal Insufficiency, Chronic

Phase 1

Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

CompletedNCT02437422

Prolong PharmaceuticalsRenal Insufficiency, Chronic

Start: 2015-06-05End: 2015-11-18Updated: 2018-05-23

Phase 2

Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

CompletedNCT02411708

Prolong PharmaceuticalsAnemia, Sickle Cell

Start: 2016-11-30End: 2017-12-31Updated: 2018-05-23

Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant

CompletedNCT02490202

Prolong PharmaceuticalsDelayed Function of Renal Transplant

Start: 2015-08-31End: 2016-10-31Updated: 2016-10-27

SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer

CompletedNCT02600390

Prolong PharmaceuticalsLeg Ulcer

Start: 2016-03-31End: 2016-11-30Updated: 2017-02-28

A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients

WithdrawnNCT02658162

Prolong PharmaceuticalsDelayed Function of Renal Transplant

Start: 2016-02-29End: 2018-12-31Updated: 2018-05-25

Related Papers

Pegylated Carboxyhemoglobin Bovine (SANGUINATE®) Restores RBCs Roundness and Reduces Pain during a Sickle Cell Vaso-Occlusive Crisis

Blood2017-12-075 citations

A phase Ib, open‐label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of <scp>SANGUINATE</scp> infusion in patients with end‐stage renal disease

Clinical Transplantation2017-11-1517 citations